Form 4: CervoMed Director David Quigley Receives Stock Option Grant

Director David Quigley was granted options to purchase 8,150 shares of CervoMed Inc. common stock following his election to the board.

Summary

• Director David Quigley received a grant of 8,150 stock options on June 8, 2026.
• The grant was issued in connection with his election to the board of directors at the 2026 Annual Meeting of Stockholders.
• The options have an exercise price of $2.91 per share.
• The options vest in 1/12th increments monthly over one year, starting June 30, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with shareholders through equity-based compensation.

Negatives

• Dilutive impact of new option grants on existing shareholders.

Risks

• Continued service requirement for vesting of the equity award.

Future Outlook

The options vest monthly over a one-year period, contingent upon the director's continued service to the company.

Industry Context

StockSavvy.ai notes that standard equity grants for non-employee directors are a common practice in the biotechnology sector to attract and retain board talent while aligning incentives with long-term shareholder value.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with standard non-employee director compensation policies for small-cap biotechnology firms.

Corporate Governance

Stakeholder Impact

• Shareholders: Minor dilution from the issuance of new options.

Next Steps

• Vesting of options in 1/12th increments starting June 30, 2026.

Key Dates

Keywords

CervoMed, CRVO, Form 4, Director Compensation, Stock Options, Insider Transaction